Orchestra BioMed Holdings, Inc. (OBIO)
(Delayed Data from NSDQ)
$6.70 USD
+0.02 (0.30%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $6.71 +0.01 (0.15%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Income Statements
Fiscal Year end for Orchestra BioMed Holdings, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 3 | 0 | 0 | 0 | NA |
Cost Of Goods | 0 | 0 | 0 | 0 | NA |
Gross Profit | 3 | 0 | 0 | 0 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 54 | 3 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -52 | -3 | 0 | 0 | 0 |
Non-Operating Income | 2 | 0 | 0 | 0 | NA |
Interest Expense | 0 | 0 | 0 | 0 | NA |
Pretax Income | -49 | -3 | 0 | 0 | NA |
Income Taxes | 0 | 0 | 0 | 0 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -49 | -3 | 0 | 0 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -49 | -3 | 0 | 0 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -51 | -3 | 0 | 0 | 0 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | NA |
Income After Depreciation & Amortization | -52 | -3 | 0 | 0 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 33.23 | NA | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | -1.48 | NA | NA | NA | NA |
Diluted Net EPS (GAAP) | -1.48 | -0.17 | -0.02 | -0.04 | NA |
Fiscal Year end for Orchestra BioMed Holdings, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.78 | 0.62 | 0.26 | 0.42 | 0.92 |
Cost Of Goods | 0.04 | 0.03 | 0.05 | 0.04 | 0.05 |
Gross Profit | 0.73 | 0.59 | 0.22 | 0.38 | 0.86 |
SG&A, R&D, and Dept/Amort Expenses | 17.60 | 15.01 | 12.70 | 14.90 | 13.82 |
Income After SG&A, R&D, and Dept/Amort Expenses | -16.87 | -14.42 | -12.48 | -14.52 | -12.96 |
Non-Operating Income | 0.88 | 0.96 | -0.34 | 1.21 | 0.91 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -15.98 | -13.46 | -12.82 | -13.32 | -12.05 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -15.98 | -13.46 | -12.82 | -13.32 | -12.05 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -15.98 | -13.46 | -12.82 | -13.32 | -12.05 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 35.80 | 35.78 | 34.64 | 35.24 | 34.61 |
Diluted EPS Before Non-Recurring Items | -0.45 | -0.38 | -0.37 | -0.38 | -0.35 |
Diluted Net EPS (GAAP) | -0.45 | -0.38 | -0.35 | -0.38 | -0.35 |